Search research articles
Contact Us
Filters
Showing results (251-260 of 282) with videos related to
Page
of 29
Sort By:
Leukemia & Lymphoma
|
February 1, 1997
A phase-II study with idarubicin, ifosfamide and VP-16 (IIVP-16) in patients with refractory or relapsed aggressive and high grade non-Hodgkin's lymphoma
A Engert, R Schnell, F Küpper, et al.
British Journal of Cancer
|
March 17, 2011
Randomised phase II trial of gemcitabine plus vinorelbine vs gemcitabine plus cisplatin vs gemcitabine plus capecitabine in patients with pretreated metastatic breast cancer
H J Stemmler, D diGioia, W Freier, et al.
Journal of Molecular Medicine (Berlin, Germany)
|
April 26, 2022
ASK1 is a novel molecular target for preventing aminoglycoside-induced hair cell death
Jacqueline M Ogier, Yujing Gao, Eileen M Dunne, et al.
Endocrinology
|
February 8, 2026
Balcinrenone shows a unique regulation of potassium excretion in streptozotocin-induced diabetes in male mice
Monica Kanki, Elliott Vivekanantham, Gregory H Tesch, et al.
Blood
|
January 15, 1997
A phase-I study of an anti-CD25 ricin A-chain immunotoxin (RFT5-SMPT-dgA) in patients with refractory Hodgkin's lymphoma
A Engert, V Diehl, R Schnell, et al.
Journal of Molecular Medicine (Berlin, Germany)
|
May 10, 2022
Correction to: ASK1 is a novel molecular target for preventing aminoglycoside‑induced hair cell death
Jacqueline M Ogier, Yujing Gao, Eileen M Dunne, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 11, 2013
Evaluation of Mucin-1 protein and mRNA expression as prognostic and predictive markers after neoadjuvant chemotherapy for breast cancer
B V Sinn, G von Minckwitz, C Denkert, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 2, 2017
German Adjuvant Intergroup Node-positive Study (GAIN): a phase III trial comparing two dose-dense regimens (iddEPC versus ddEC-PwX) in high-risk early breast cancer patients
V Möbus, G von Minckwitz, C Jackisch, et al.
Geburtshilfe Und Frauenheilkunde
|
February 17, 2015
Biomarkers in Patients with Metastatic Breast Cancer and the PRAEGNANT Study Network
P A Fasching, S Y Brucker, T N Fehm, et al.
Blood
|
December 9, 1998
Moderate dose escalation for advanced stage Hodgkin's disease using the bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone scheme and adjuvant radiotherapy: a study of the German Hodgkin's Lymphoma Study Group
H Tesch, V Diehl, B Lathan, et al.
Page
of 29
Search research articles
Search
Showing results (251-260 of 282) with videos related to
Sort By:
Page
of 29
Leukemia & Lymphoma
|
February 1, 1997
A phase-II study with idarubicin, ifosfamide and VP-16 (IIVP-16) in patients with refractory or relapsed aggressive and high grade non-Hodgkin's lymphoma
A Engert, R Schnell, F Küpper, et al.
British Journal of Cancer
|
March 17, 2011
Randomised phase II trial of gemcitabine plus vinorelbine vs gemcitabine plus cisplatin vs gemcitabine plus capecitabine in patients with pretreated metastatic breast cancer
H J Stemmler, D diGioia, W Freier, et al.
Journal of Molecular Medicine (Berlin, Germany)
|
April 26, 2022
ASK1 is a novel molecular target for preventing aminoglycoside-induced hair cell death
Jacqueline M Ogier, Yujing Gao, Eileen M Dunne, et al.
Endocrinology
|
February 8, 2026
Balcinrenone shows a unique regulation of potassium excretion in streptozotocin-induced diabetes in male mice
Monica Kanki, Elliott Vivekanantham, Gregory H Tesch, et al.
Blood
|
January 15, 1997
A phase-I study of an anti-CD25 ricin A-chain immunotoxin (RFT5-SMPT-dgA) in patients with refractory Hodgkin's lymphoma
A Engert, V Diehl, R Schnell, et al.
Journal of Molecular Medicine (Berlin, Germany)
|
May 10, 2022
Correction to: ASK1 is a novel molecular target for preventing aminoglycoside‑induced hair cell death
Jacqueline M Ogier, Yujing Gao, Eileen M Dunne, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 11, 2013
Evaluation of Mucin-1 protein and mRNA expression as prognostic and predictive markers after neoadjuvant chemotherapy for breast cancer
B V Sinn, G von Minckwitz, C Denkert, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 2, 2017
German Adjuvant Intergroup Node-positive Study (GAIN): a phase III trial comparing two dose-dense regimens (iddEPC versus ddEC-PwX) in high-risk early breast cancer patients
V Möbus, G von Minckwitz, C Jackisch, et al.
Geburtshilfe Und Frauenheilkunde
|
February 17, 2015
Biomarkers in Patients with Metastatic Breast Cancer and the PRAEGNANT Study Network
P A Fasching, S Y Brucker, T N Fehm, et al.
Blood
|
December 9, 1998
Moderate dose escalation for advanced stage Hodgkin's disease using the bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone scheme and adjuvant radiotherapy: a study of the German Hodgkin's Lymphoma Study Group
H Tesch, V Diehl, B Lathan, et al.
Page
of 29